ABSTRACT
A total of 143 premature children of the first 3 months of life (the body weight upon birth 1200-2500 g) staying at a specialized hospital, and 28 children (the body weight upon birth 1100-2500 g) under 3 years staying at a pulmonological sanatorium were examined. Studies on enzymatic functions (uropepsin, glutathione, protease and lipase activity in the blood serum) revealed a decrease in adaptation processes in premature children with acute pneumonia, and during reconvalescence in children with hypotrophy. In premature neonates on formula feeding with a mixture of "Malyutka", the content of total lipids, cholesterol and phospholipids was lower than in children on natural feeding. The content of free fatty acids and acetone tended towards an increase during formula feeding. Pneumonia incidence in premature children was 4 times higher in the first year of life and 2 1/2-2 times higher in the second and third years of life, as compared to full-term babies. The respiratory diseases in premature children were followed by the asthmatic syndrome. The results obtained may be used for the development of dietetic management of premature children with pneumonia and hypotrophy.
Subject(s)
Infant, Premature, Diseases/metabolism , Pneumonia/metabolism , Body Weight , Bottle Feeding , Breast Feeding , Convalescence , Endopeptidases/metabolism , Gastric Mucosa/metabolism , Glutathione/metabolism , Humans , Infant , Infant, Newborn , Infant, Premature , LipolysisSubject(s)
Biliary Tract Diseases/therapy , Hospitals, District , Hospitals, Pediatric , Hospitals, Public , Hospitals, Special , Adolescent , Child , Child, Preschool , Evaluation Studies as Topic , Female , Health Resorts , Humans , Length of Stay , Male , Russia , SeasonsABSTRACT
High efficacy of prodigiozan, a bacterial polysaccharide used in the form of inhalation in combined therapy of 123 children at the age of 3 to 14 with nonspecific bronchopulmonary pathologic conditions was shown. The drug was administered by means of inhalators UI-I and PAI-I once every 4--5 days in the form of 0.02 per cent solution prepared in situ. The single and the course doses were 100--400 and 300--2000 micrograms respectively. The positive therapeutic effect was observed in 85.0 per cent of the patients: improvement of the patient state was registered 4--6 days earlier than that in the control group, the indices of the respiration mechanics and nonspecific immunity (titers of lysozyme and complement) also improved. The rate of viral respiratory diseases among the children treated with prodigiozan decreased 2.5 times. High efficacy and physiological character of the aerosol method for administration of prodigiozan used the the first time in pediatry provided its recommendation for wide use.
